Biological monitoring of cancer chemoprevention

R. Pillai, H. S. Garewal, S. Wood, Ronald R Watson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A major limiting factor in the successful implementation of cancer chemoprevention trials has been the determination of endpoints to measure efficacy and success. The use of the ultimate goal of such trials, namely, cancer incidence, as an endpoint has serious feasibility problems, including the need for large numbers of participants, long follow-up periods, and high costs. The application of biological markers as intermediate endpoints to reveal responses to chemopreventive agents within a short time and to act as surrogates for cancer is an attractive concept worthy of intense investigation. This study reviews some potential biological markers, including genetic, cellular, biochemical, and immunological, as well as their possible application to cancer chemoprevention.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalJournal of Surgical Oncology
Volume51
Issue number3
DOIs
StatePublished - 1992

Fingerprint

Environmental Monitoring
Chemoprevention
Neoplasms
Biomarkers
Endpoint Determination
Molecular Biology
Costs and Cost Analysis
Incidence

Keywords

  • biological markers
  • growth factors
  • intermediate endpoints
  • micronutrients
  • oncogenes

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Biological monitoring of cancer chemoprevention. / Pillai, R.; Garewal, H. S.; Wood, S.; Watson, Ronald R.

In: Journal of Surgical Oncology, Vol. 51, No. 3, 1992, p. 195-202.

Research output: Contribution to journalArticle

Pillai, R. ; Garewal, H. S. ; Wood, S. ; Watson, Ronald R. / Biological monitoring of cancer chemoprevention. In: Journal of Surgical Oncology. 1992 ; Vol. 51, No. 3. pp. 195-202.
@article{3abfa5a633a1467b88e2484ea59d5aff,
title = "Biological monitoring of cancer chemoprevention",
abstract = "A major limiting factor in the successful implementation of cancer chemoprevention trials has been the determination of endpoints to measure efficacy and success. The use of the ultimate goal of such trials, namely, cancer incidence, as an endpoint has serious feasibility problems, including the need for large numbers of participants, long follow-up periods, and high costs. The application of biological markers as intermediate endpoints to reveal responses to chemopreventive agents within a short time and to act as surrogates for cancer is an attractive concept worthy of intense investigation. This study reviews some potential biological markers, including genetic, cellular, biochemical, and immunological, as well as their possible application to cancer chemoprevention.",
keywords = "biological markers, growth factors, intermediate endpoints, micronutrients, oncogenes",
author = "R. Pillai and Garewal, {H. S.} and S. Wood and Watson, {Ronald R}",
year = "1992",
doi = "10.1002/jso.2930510314",
language = "English (US)",
volume = "51",
pages = "195--202",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Biological monitoring of cancer chemoprevention

AU - Pillai, R.

AU - Garewal, H. S.

AU - Wood, S.

AU - Watson, Ronald R

PY - 1992

Y1 - 1992

N2 - A major limiting factor in the successful implementation of cancer chemoprevention trials has been the determination of endpoints to measure efficacy and success. The use of the ultimate goal of such trials, namely, cancer incidence, as an endpoint has serious feasibility problems, including the need for large numbers of participants, long follow-up periods, and high costs. The application of biological markers as intermediate endpoints to reveal responses to chemopreventive agents within a short time and to act as surrogates for cancer is an attractive concept worthy of intense investigation. This study reviews some potential biological markers, including genetic, cellular, biochemical, and immunological, as well as their possible application to cancer chemoprevention.

AB - A major limiting factor in the successful implementation of cancer chemoprevention trials has been the determination of endpoints to measure efficacy and success. The use of the ultimate goal of such trials, namely, cancer incidence, as an endpoint has serious feasibility problems, including the need for large numbers of participants, long follow-up periods, and high costs. The application of biological markers as intermediate endpoints to reveal responses to chemopreventive agents within a short time and to act as surrogates for cancer is an attractive concept worthy of intense investigation. This study reviews some potential biological markers, including genetic, cellular, biochemical, and immunological, as well as their possible application to cancer chemoprevention.

KW - biological markers

KW - growth factors

KW - intermediate endpoints

KW - micronutrients

KW - oncogenes

UR - http://www.scopus.com/inward/record.url?scp=0026471020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026471020&partnerID=8YFLogxK

U2 - 10.1002/jso.2930510314

DO - 10.1002/jso.2930510314

M3 - Article

VL - 51

SP - 195

EP - 202

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -